Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.
The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.
It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials.
Incannex Hea
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 24 | -0.38 | - |
| Feb 26, 24 | -0.33 | - |
| Sep 30, 23 | -0.00 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | N/A Decreased by N/A% | N/A Increased by +100.00% | - - |
| Mar 31, 23 | 6.55 K Increased by +N/A% | -3.73 M Increased by +0.85% | Decreased by -56.93 K% - |
| Dec 31, 22 | N/A Decreased by -100.00% | -3.76 M Decreased by -85.86% | - - |
| Sep 30, 22 | N/A Decreased by -100.00% | -3.76 M Decreased by -85.86% | - - |
| Jun 30, 22 | N/A Decreased by -100.00% | -3.76 M Decreased by -85.86% | - - |
| Mar 31, 22 | N/A Decreased by -100.00% | -3.76 M Decreased by -85.86% | - - |
| Dec 31, 21 | 474.40 K Increased by +213.71% | -2.02 M Decreased by -72.17% | Decreased by -426.22% Increased by +45.12% |
| Sep 30, 21 | 474.40 K Increased by +213.71% | -2.02 M Decreased by -72.17% | Decreased by -426.22% Increased by +45.12% |